Production (Stage)
Calidi Biotherapeutics, Inc.
CLDI
$0.32
-$0.025-7.25%
AMEX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.64M | 2.21M | 3.07M | 3.61M | 4.01M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.06M | 4.03M | 5.23M | 5.77M | 6.75M |
| Operating Income | -5.06M | -4.03M | -5.23M | -5.77M | -6.75M |
| Income Before Tax | -5.06M | -4.15M | -5.07M | -5.76M | -7.22M |
| Income Tax Expenses | 3.00K | 3.00K | -1.00K | 8.00K | 4.00K |
| Earnings from Continuing Operations | -5.06M | -4.15M | -5.07M | -5.77M | -7.23M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 76.00K | 51.00K | 15.00K | -- | -- |
| Net Income | -4.99M | -4.10M | -5.05M | -5.77M | -7.23M |
| EBIT | -5.06M | -4.03M | -5.23M | -5.77M | -6.75M |
| EBITDA | -4.97M | -3.93M | -5.12M | -5.67M | -6.65M |
| EPS Basic | -0.18 | -0.27 | -0.65 | -1.40 | -2.03 |
| Normalized Basic EPS | -0.11 | -0.17 | -0.40 | -0.68 | -1.27 |
| EPS Diluted | -0.18 | -0.27 | -0.65 | -1.40 | -2.03 |
| Normalized Diluted EPS | -0.11 | -0.17 | -0.40 | -0.68 | -1.27 |
| Average Basic Shares Outstanding | 27.09M | 15.29M | 7.82M | 5.33M | 3.56M |
| Average Diluted Shares Outstanding | 27.09M | 15.29M | 7.82M | 5.33M | 3.56M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |